In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...

Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

The company has also reported positive data for PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, and ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...